BIRC2 and breast carcinoma: Our observations are partly in line with previously published studies, revealing rapid degradation of cIAP1 and cIAP2 and slower degradation of XIAP in MDA-MB-231 breast carcinoma cells [15] or downregulation of cIAP1, cIAP2 and XIAP levels in MV4-11, OCI-AML3 and NB4 acute myeloid leukemia cells [20, 22] upon BV6 treatment.